Journal
FRONTIERS IN ONCOLOGY
Volume 3, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2013.00135
Keywords
epigenetics; DNA methylation; hypomethylating agent; histone deacetylase inhibitors; microRNAs; lung cancer
Categories
Funding
- National Cancer Institute [P3OCA014089]
- NATIONAL CANCER INSTITUTE [P30CA014089] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Epigenetic deregulation of gene function has been strongly implicated in carcinogenesis and is one of the mechanisms contributing to the development of lung cancer. The inherent reversibility of epigenetic alterations makes them viable therapeutic targets. Here, we review the therapeutic implications of epigenetic changes in lung cancer, and recent advances in therapeutic strategies targeting DNA methylation and histone acetylation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
